Publications by authors named "Maria Eriksson Svensson"
Article Synopsis
- This study looked at people in Sweden who had kidney disease but didn't know it, to see how often they got diagnosed and treated.
- Out of nearly 100,000 people with undiagnosed kidney disease, only about 1 in 3 were diagnosed in five years, and not many were treated with the right medications.
- If all of them had received proper treatment, many deaths and heart problems could have been avoided, showing there's a big opportunity to help these patients better.
Objective: The prevalence of chronic kidney disease (CKD) is increasing globally, and CKD is closely related to cardiovascular disease (CVD). CKD and CVD share several risk factors (RF), such as diabetes, hypertension, obesity and smoking, and the prevalence of these RF has changed during the last decades, and we aimed to study the effect on renal function over time.
Design: Repeated cross-sectional population-based studies.
Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden.
Eur Heart J Qual Care Clin Outcomes
January 2022
Aims: To assess the cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab added to standard-of-care lipid-lowering treatment [maximum tolerated dose (MTD) of statin and ezetimibe] in Swedish patients with a history of myocardial infarction (MI).
Methods And Results: Cost-effectiveness was evaluated using a Markov model based on Swedish observational data on cardiovascular event rates and efficacy from the FOURIER trial. Three risk profiles were considered: recent MI in the previous year; history of MI with a risk factor; and history of MI with a second event within 2 years.